Antibodies for bioanalysis and drug monitoring of canakinumab

Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug canakinumab (Ilaris) using our range of ready-made anti-idiotypic antibodies.

  • Inhibitory antibodies specific to canakinumab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch-to-batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Canakinumab

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Canakinumab

Inhibitory

Type 1

HCA417

AbD54331ia

hIgG1

1.5

ADA assay

Order HCA417

HCA418

AbD54111ia

hIgG1

7.7

ADA assay

Order HCA418

HCA419

AbD54116ia

hIgG1

9.6

ADA assay

Order HCA419

TZA063

AbD54116ad

Fab-F-Spy2-H1

9.6

PK bridging ELISA (capture)

Order TZA063

TZA064

AbD54331ad

Fab-F-Spy2-H1

1.5

PK bridging ELISA (detection)

Order TZA064

TZA064P

AbD54331pap

Fab2-FH-X22-HRP2

1.5

PK bridging ELISA (detection)

Order TZA064P
Coming soon

* Affinity measured in the monovalent Fab format.
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
Fab2-FH-X22-HRP= Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags, and Fab-SpyTag coupled to HRP conjugated BiCatcher.


Anti-Canakinumab Inhibitory Antibodies (Type 1)

Type 1 anti-canakinumab antibodies inhibit the binding of the drug canakinumab to its target, the human interleukin-1β (IL-1β). They are ideal for the development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibodies in fully human IgG1 format are suitable as surrogate positive controls or calibrators for an anti-drug antibody (ADA) assay.


ELISA Protocols to Get You Started

PK Bridging ELISA


Fig. 1. Canakinumab PK bridging ELISA using antibodies TZA063 and TZA064P.

Fig. 1. Canakinumab PK bridging ELISA using antibodies TZA063 and TZA064P.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.


ADA Bridging ELISA


Fig. 2. Canakinumab ADA bridging ELISA using antibodies HCA417, HCA418, and HCA419.

Fig. 2. Canakinumab ADA bridging ELISA using antibodies HCA417, HCA418, and HCA419.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).


Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.